Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-Blind Clinical Trials

2005782 citationsJournal Article

Authors

Kenneth D Boffard · University of the Witwatersrand

Bruno Riou

Abstract

Recombinant FVIIa resulted in a significant reduction in RBC transfusion in severe blunt trauma. Similar trends were observed in penetrating trauma. The safety of rFVIIa was established in these trauma populations within the investigated dose range.

Topics & Keywords

Trauma, Hemostasis, Coagulopathy, Resuscitation Trauma and Emergency Care Studies Hemophilia Treatment and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Trauma: Injury, Infection, and Critical Care

Volume 59, Issue 1, pp. 8-18

DOI: 10.1097/01.ta.0000171453.37949.b7

Field-Weighted Citation Impact: 62.04